Pharma stocks wobble
Pharmaceutical shares fell after Donald Trump signalled tariffs on medicines, a market report says. (jainam.in) The note stresses that medicines have traditionally faced low barriers because they're essential to health systems, so the prospect of tariffs prompted rapid investor selling. (jainam.in)
Drug stocks fell after President Donald Trump moved from tariff threats to a formal April 2 proclamation imposing new duties on some imported patented medicines. (whitehouse.gov) The White House said the headline rate is 100% on patented pharmaceutical products and ingredients under Section 232 of the Trade Expansion Act, with the tariffs starting in 120 days for larger companies and 180 days for smaller ones. (whitehouse.gov) The policy is narrower than the headline number suggests. The White House said generic drugs and biosimilars are exempt for now, companies that sign both United States pricing and onshoring deals can get a 0% rate through January 20, 2029, and companies that only sign onshoring deals face 20%. (whitehouse.gov) That still hit a sector built on cross-border manufacturing. Trump’s proclamation said about 53% of patented pharmaceutical products sold in the United States were produced abroad as of 2025, and only 15% of patented active pharmaceutical ingredients by volume were made domestically. (whitehouse.gov) The administration framed the move as a supply-chain and national-security measure, saying imported pharmaceuticals and ingredients threaten to impair national security and public health. (whitehouse.gov) The carveouts also show where the pressure is aimed. Politico reported the tariffs mainly target brand-name drugs, while orphan drugs, generics and some companies with United States manufacturing commitments were spared or given lower rates. (politico.com) Trade partners immediately sought exceptions. Reuters reported on April 2 that Britain finalized a United States-United Kingdom pharmaceutical deal that gives UK-made medicines tariff-free access to the American market. (msn.com) Drugmakers and biotech groups said the policy could backfire. Steve Ubl of Pharmaceutical Research and Manufacturers of America said tariffs on medicines would increase costs, and Biotechnology Innovation Organization chief John Crowley said smaller companies often cannot build dedicated plants on short notice. (politico.com) The market reaction reflects that tension: a White House push to bring drug production home colliding with an industry that still makes a large share of patented medicines and key ingredients outside the United States. (whitehouse.gov)
